IJCS | Volume 31, Nº5, September / October 2018

489 Figure 3 - Adverse event-free survival according to TTR and SAMe-TT 2 R 2 score. Pivatto Júnior et al. SAMe-TT 2 R 2 score forVTE patients? Int J Cardiovasc Sci. 2018;31(5)483-491 Original Article patients with VTE, the AUC indicated that the score has a unsatisfactory predictive value (< 0.7), as observed in the present analysis (AUC = 0.595). The values described by Demelo-Rodríguez et al. 5 (AUC = 0.517) and Palareti et al. 9 (AUC = 0.52) were considered poor (0.5 < AUC < 0.6), while the value described by Kataruka et al. 8 (AUC = 0.65) was considered only fair (0.6 ≤ AUC < 0.7). This study has some limitations. The retrospective design has inherent limitations that may have influenced the quality and consistency of the data collected. Nevertheless, we believe that therewas no significant loss of data required for the study, since, at our institution, patients receive systematic care by means of protocols and structured outpatient visits. Thus, most data required for the analysis were systematically collected during outpatient visits. Moreover, the comorbidities were carefully defined to reduce the possibility of misclassification. Another limitation is that the review of medical records allows the identification of only in- hospital adverse events or events reported by patients during outpatient visits, and some events may have been underestimated. Finally, although the fact that the study was performed at a single center ensured a more organized and consistent follow-up care of patients in this cohort, this might have decreased its external validity. Conclusion Based on the present findings, the SAMe-TT 2 R 2 score does not seem to be a useful tool for determining which patients with VTE are more likely to achieve a good TTR and to have adverse events during anticoagulation with VKA. Population differences between patients with AF and VTE may explain the differences in score performance and highlight the importance of studying scores in specific populations before their clinical application. We believe that our data, derived from a cohort of patients with VTE from a South American Log-rank p = 0.136